Chromogranin B and Secretogranin II in Transgenic Mice Overexpressing Human APP751 with the London (V717I) and Swedish (K670M/N671L) Mutations and in Alzheimer Patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2008-03-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3233/JAD-2008-13202PMID 18376054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Chromogranin B and Secretogranin II in Transgenic Mice Overexpressing Human APP751 with the London (V717I) and Swedish (K670M/N671L) Mutations and in

  2008cited by this paper
• Spatial relationship between synapse loss and β‐amyloid deposition in Tg2576 mice

  2007cited by this paper
• Chromogranin A activates diverse pathways mediating inducible nitric oxide expression and apoptosis in primary microglia.

  2007cited by this paper
• A dynamic relationship between intracellular and extracellular pools of Abeta.

  2006cited by this paper
• Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis

  2006cited by this paper
• Molecular basis of neuroendocrine cell type‐specific expression of the chromogranin B gene: crucial role of the transcription factors CREB, AP‐2, Egr‐1 and Sp1

  2006cited by this paper
• Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

  2006cited by this paper
• Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.

  2005cited by this paper
• Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease

  2005cited by this paper
• The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects

  2004cited by this paper
• Chromogranin peptides in Alzheimer's disease.

  2004influential reference
• Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain

  2004cited by this paper
• Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice.

  2004cited by this paper
• Secretoneurin, an Angiogenic Neuropeptide, Induces Postnatal Vasculogenesis

  2004cited by this paper
• The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.

  2004cited by this paper
• A review on electron microscopy and neurotransmitter systems.

  2004cited by this paper
• Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.

  2004cited by this paper
• Expression of Regulated Secretory Proteins Is Sufficient to Generate Granule-like Structures in Constitutively Secreting Cells*

  2004cited by this paper
• A modified β‐amyloid hypothesis: intraneuronal accumulation of the β‐amyloid peptide – the first step of a fatal cascade

  2004cited by this paper
• The chromogranin-secretogranin family.

  2003cited by this paper
• The mouse brain in stereotaxic coordinates

  2003cited by this paper
• The chromogranin-secretogranin family.

  2003cited by this paper
• A Functional Interaction between Chromogranin B and the Inositol 1,4,5-Trisphosphate Receptor/Ca2+ Channel*

  2003cited by this paper
• Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia.

  2002cited by this paper
• Synaptic proteins in Alzheimer’s disease

  2002cited by this paper
• Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up‐regulated in Alzheimer's disease

  2002cited by this paper
• Neuroendocrine secretory protein 55: a novel marker for the constitutive secretory pathway.

  2002cited by this paper
• Polymorphisms of chromogranin B gene associated with schizophrenia in Chinese Han population.

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42

  2001influential reference
• Key Factors in Alzheimer's Disease: β‐amyloid Precursor Protein Processing, Metabolism and Intraneuronal Transport

  2001cited by this paper
• Proteomic analysis of proteins in PC12 cells before and after treatment with nerve growth factor: increased levels of a 43-kDa chromogranin B-derived fragment during neuronal differentiation.

  2001cited by this paper
• Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice.

  2001cited by this paper
• Lithium Ions Up‐Regulate mRNAs Encoding Dense‐Core Vesicle Proteins in Nerve Growth Factor‐Differentiated PC12 Cells

  2000cited by this paper
• Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer’s disease

  2000cited by this paper
• Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia.

  1999cited by this paper
• Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease.

  1999cited by this paper
• PE-11, a peptide derived from chromogranin B, in the human brain.

  1999cited by this paper
• Synaptic loss reflected by secretoneurin‐like immunoreactivity in the human hippocampus in Alzheimer's disease

  1998cited by this paper
• Neuropathology of Alzheimer's disease: a critical update.

  1998cited by this paper
• Differential increases in chromogranins, but not synapsin I, in cortical neurons following spreading depression: implications for functional roles and transmitter peptide release

  1998cited by this paper
• Chromogranin B (secretogranin I), a neuroendocrine‐regulated secretory protein, is sorted to exocrine secretory granules in transgenic mice

  1998cited by this paper
• Dystrophic Neurites of Senile Plaques are Defective in Proteins Involved in Exocytosis and Neurotransmission

  1998cited by this paper
• Neuropathological Assessment of Alzheimer's Disease: The Experience of the Consortium to Establish a Registry for Alzheimer's Disease

  1997cited by this paper
• Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

  1997cited by this paper
• Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study

  1996cited by this paper
• pH- and Ca(2+)-dependent aggregation property of secretory vesicle matrix proteins and the potential role of chromogranins A and B in secretory vesicle biogenesis.

  1996cited by this paper
• Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease

  1996cited by this paper
• Secretogranin II Is Synthesized and Secreted in Astrocyte Cultures

  1993cited by this paper
• Synaptic Pathology of Alzheimer's Disease a

  1993cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• Distribution of Secretoneurin‐like Immunoreactivity in Comparison with Substance P‐ and Enkephalin‐like Immunoreactivities in Various Human Forebrain Regions

  1993cited by this paper
• Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles.

  1992cited by this paper
• Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

  1991cited by this paper
• The distribution of chromogranin A—like immunoreactivity in the human hippocampus coincides with the pattern of resistance to epilepsy‐induced neuronal damage

  1990cited by this paper
• Diagnosis of Alzheimer's disease.

  1988cited by this paper
• The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease

  1988cited by this paper
• The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimerʼs disease: a clinicopathologic study of 57 cases

  1988cited by this paper
• Diagnosis of Alzheimer's disease.

  1985cited by this paper

• Capturing biomarkers associated with Alzheimer disease subtypes using data distribution characteristics

  2024cites this paper
• Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.

  2019cites this paper
• Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer’s Disease

  2019cites this paper
• Neuropeptides in Alzheimer's Disease: An Update.

  2019cites this paper
• Proteomic study on neurite responses to oxidative stress: search for differentially expressed proteins in isolated neurites of N1E-115 cells

  2018cites this paper
• Mice lacking chromogranins exhibit increased aggressive and depression-like behaviour.

  2015cites this paper
• L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model

  2015cites this paper
• Drosophila Orthologs, Expressed Specifically in Courting Zebra Finch Males, are Engaged in Courtship

  2013cites this paper
• Enrichment of the inositol 1,4,5-trisphosphate receptor/Ca2+ channels in secretory granules and essential roles of chromogranins.

  2012cites this paper
• Monocular enucleation profoundly reduces secretogranin II expression in adult mouse visual cortex.

  2011cites this paper
• Chromogranin peptides in brain diseases

  2011cites this paper
• Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain

  2010cites this paper